These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 29558865)

  • 1. GP2015 as a promising therapy for rheumatoid arthritis.
    Fitton J; Giollo A; Buch MH
    Expert Opin Biol Ther; 2018 Apr; 18(4):477-481. PubMed ID: 29558865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
    Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
    Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GP2015: An Etanercept Biosimilar.
    Deeks ED
    BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
    Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).
    Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A
    Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
    Chadwick L; Zhao S; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis.
    Song YW; Park YB; Kim J
    Expert Opin Biol Ther; 2021 Jan; 21(1):1-8. PubMed ID: 31801395
    [No Abstract]   [Full Text] [Related]  

  • 8. Etanercept for the treatment of rheumatoid arthritis.
    Zhao S; Mysler E; Moots RJ
    Immunotherapy; 2018 Mar; 10(6):433-445. PubMed ID: 29482402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015.
    Poetzl J; Arlt I; von Richter O; Wöhling H; Afonso M; Schaffar G
    J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):e130-e132. PubMed ID: 29024096
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.
    Emery P; Vencovský J; Sylwestrzak A; Leszczyński P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
    Ann Rheum Dis; 2017 Jan; 76(1):51-57. PubMed ID: 26150601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
    Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
    Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.
    Bae SC; Kim J; Choe JY; Park W; Lee SH; Park YB; Shim SC; Lee SS; Sung YK; Choi CB; Lee SR; Park H; Ahn Y;
    Ann Rheum Dis; 2017 Jan; 76(1):65-71. PubMed ID: 26905864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.
    Matucci-Cerinic M; Allanore Y; Kavanaugh A; Buch MH; Schulze-Koops H; Kucharz EJ; Woehling H; Babic G; Poetzl J; Davis A; Schwebig A
    RMD Open; 2018; 4(2):e000757. PubMed ID: 30487998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept biosimilar SB-4.
    Pelechas E; Drosos AA
    Expert Opin Biol Ther; 2019 Mar; 19(3):173-179. PubMed ID: 30616405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
    Park MC; Matsuno H; Kim J; Park SH; Lee SH; Park YB; Lee YJ; Lee SI; Park W; Sheen DH; Choe JY; Choi CB; Hong SJ; Suh CH; Lee SS; Cha HS; Yoo B; Hur JW; Kim GT; Yoo WH; Baek HJ; Shin K; Shim SC; Yang HI; Kim HA; Park KS; Choi IA; Lee J; Tomomitsu M; Shin S; Lee J; Song YW
    Arthritis Res Ther; 2019 May; 21(1):122. PubMed ID: 31113455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABP 501 for the treatment of rheumatoid arthritis.
    Pelechas E; Voulgari PV; Drosos AA
    Expert Opin Biol Ther; 2018 Mar; 18(3):317-322. PubMed ID: 29350566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.
    von Richter O; Skerjanec A; Afonso M; Sanguino Heinrich S; Poetzl J; Woehling H; Velinova M; Koch A; Kollins D; Macke L; Wuerth G
    Br J Clin Pharmacol; 2017 Apr; 83(4):732-741. PubMed ID: 27790726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
    Tarallo M; Onishchenko K; Alexopoulos ST
    J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar.
    Strand V; Girolomoni G; Schiestl M; Ernst Mayer R; Friccius-Quecke H; McCamish M
    Curr Med Res Opin; 2017 Jun; 33(6):993-1003. PubMed ID: 28133979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.